Aptamer-Based SARS-CoV-2 Detection and Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for SARS-CoV-2 infections, such as RT-PCR, are laborious and lack sensitivity and accuracy, and existing antibodies targeting the receptor-binding domain (RBD) of the spike glycoprotein are ineffective due to mutations, necessitating a more reliable and specific detection method.
Innovation Solution
Development of aptamers that bind to the SARS-CoV-2 spike glycoprotein without interfering with the RBD's interaction with ACE2, utilizing specific nucleotide sequences that provide high affinity and specificity for diagnostic and therapeutic applications, including use in nasal sprays and rapid testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RT-PCR is used for SARS-CoV-2 detection, then detection capability is achieved, but the process is laborious and time-consuming
Solution Approach 1:
The patent replaces the complex mechanical and chemical amplification process of RT-PCR with a direct aptamer-based binding assay. The aptamers specifically bind to the SARS-CoV-2 spike protein, enabling detection through simple binding events that can be read out optically, eliminating the need for thermal cycling and nucleic acid amplification steps.
Solution Approach 2:
The patent uses aptamers as molecular copies or proxies for detecting the viral presence. Instead of amplifying and detecting viral genetic material through multiple cycles, the aptamers directly bind to and mark the spike protein, providing a simplified copy-based detection mechanism that is faster and equally reliable.
2Reliability
If antibodies targeting RBD are used for treatment, then neutralization is achieved, but mutations in RBD cause ineffectiveness
Solution Approach 1:
Instead of targeting the RBD region of the spike protein (which is prone to mutations), the patent inverts the approach by using aptamers that bind to other conserved regions of the spike glycoprotein. This alternative targeting strategy avoids the mutation-prone RBD while still achieving effective neutralization and detection.
Solution Approach 2:
The patent changes the binding parameters by switching from antibody-protein interactions (which are sensitive to RBD mutations) to aptamer-protein interactions that target conserved regions. This parameter change in binding specificity and target region provides resistance to viral mutations while maintaining neutralization effectiveness.
3Measurement precision
If aptamers are used for SARS-CoV-2 detection, then sensitivity and specificity are improved, but production complexity increases
Solution Approach 1:
The patent employs aptamers that can be synthesized chemically as disposable reagents for detection. These chemically synthesized aptamers eliminate the need for complex biological production systems, allowing for simple, scalable manufacturing that does not require cell cultures or purification facilities, thus reducing production complexity while maintaining high detection precision.
4Ease of manufacture
If chemically synthesized aptamers are used, then manufacturing cost and time are reduced, but regulatory compliance complexity increases
Solution Approach 1:
The patent utilizes chemically synthesized aptamers as disposable diagnostic reagents that can be produced through standardized chemical synthesis processes. These processes are inherently more controllable and scalable than biological production, and when implemented in GMP-compliant facilities, they provide both cost efficiency and regulatory compliance, eliminating the need for complex cell culture and purification infrastructure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers enable fast, reliable, and cost-effective detection and potential treatment of SARS-CoV-2 infections by recognizing the spike glycoprotein with high specificity and inhibiting viral infection, offering a superior alternative to existing diagnostic and therapeutic approaches.
Implementation Method 1
Aptamers are single chained nucleic acids, folding into well-defined three-dimensional shapes based on which they recognise target structures with high affinity and specificity
Data Source
AI summary
The present invention relates to an aptamer not binding to the receptor-binding domain of the SARS-CoV-2 spike glycoprotein nor inhibiting the interaction of the receptor-binding domain (RED) of spike glycoprotein with angiotensin-converting enzyme II (ACE2) and/or comprising or consisting of a nucleotide sequence SEQ ID NO: 1, a composition comprising the aptamer, and the use of the aptamer in the detection of SARS-CoV-2 or diagnosis or treatment of a SARS-CoV-2 infection.